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MaOBJECTIVES This study sought to validate exercise capacity (EC) as a surrogate for mortality, hospitalization, and
health-related quality of life (HRQOL).
BACKGROUND EC is often used as a primary outcome in exercise-based cardiac rehabilitation (CR) trials of heart failure
(HF) via direct cardiorespiratory assessment of maximum oxygen uptake (VO2peak) or through submaximal tests, such as
the 6-min walk test (6MWT).
METHODS After a systematic review, 31 randomized trials of exercise-based CR compared with no exercise control (4,784
HF patients) were included. Outcomes were pooled using random effects meta-analyses, and inverse variance weighted
linear regression equations were ﬁtted to estimate the relationship between the CR on EC and all-cause mortality, hospi-
talization, and HRQOL. Spearman correlation coefﬁcient (r), R2 at trial level, and surrogate threshold effect (STE) were
calculated. STE represents the intercept of the prediction band of the regression line with null effect on the ﬁnal outcome.
RESULTS Exercise-based CR is associated with positive effects on EC measured through VO2peak (þ3.10 ml/kg/min;
95% conﬁdence interval [CI]: 2.01 to 4.20) or 6MWT (þ41.15 m; 95% CI: 16.68 to 65.63) compared to control. The
analyses showed a low level of association between improvements in EC (VO2peak or 6MWT) and mortality and
hospitalization. Moderate levels of correlation between EC with HRQOL were seen (e.g., R2 <52%; jrj < 0.72). Estimated
STE was an increase of 5 ml/kg/min for VO2peak and 80 m for 6MWT to predict a signiﬁcant improvement in HRQOL.
CONCLUSIONS The study results indicate that EC is a poor surrogate endpoint for mortality and hospitalization
but has moderate validity as a surrogate for HRQOL. Further research is needed to conﬁrm these ﬁndings across other
HF interventions. (J Am Coll Cardiol HF 2018;6:596–604) © 2018 The Authors. Published by Elsevier on behalf of
the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).E nhancement of exercise capacity (EC) is a keyaspect of the lifestyle and management of pa-tients with heart failure (HF) (1,2). The gold
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AB BR E V I A T I O N S
AND ACRONYM S
6MWT = 6-min walk test
CI = conﬁdence interval
CR = cardiac rehabilitation
EC = exercise capacity
HF = heart failure
HRQOL = health-related
quality of life
MET = metabolic equivalent
MLwHF = Minnesota Living
With Heart Failure
OR = odds ratio
RCT = randomized controlled
trial
STE = surrogate threshold
effect
VO2peak = peak oxygen uptake
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597Administration (4). Although it is a measure of func-
tion and clinical beneﬁt, EC is a surrogate endpoint
rather than a ﬁnal patient-relevant outcome, such as
mortality, hospital admission, or health-related
quality of life (HRQOL).
For a surrogate endpoint to be considered a valid
surrogate endpoint (i.e., an adequate substitute for
the ﬁnal outcome), several levels of evidence must be
provided (5). First, there needs to be biological plau-
sibility of the relationship between the surrogate and
the ﬁnal outcome. Second, observational or epide-
miological studies are required to show a consistent
association between the surrogate and the ﬁnal
outcome. Third, the treatment effect on the surrogate
must correspond with the treatment effect on the
ﬁnal outcome, preferably in the setting of a meta-
analysis of randomized controlled trials (RCTs).
Epidemiological studies have shown that a 1.0 meta-
bolic equivalent (MET) (1 MET ¼ 3.5 ml/kg/min) in-
crease in VO2peak translates into a 12% risk reduction
in mortality in individuals with existing cardiovas-
cular disease, including HF (6). However, to our
knowledge no previous study has assessed the val-
idity of EC as a surrogate endpoint for HF in a RCT
setting.SEE PAGE 605Using RCTs of exercise-based cardiac rehabilitation
(CR) in patients with HF, we sought to address the
following 2 research questions: 1) is there an associ-
ation between the intervention effect of CR in HF on
EC, and each of mortality, hospitalization, and
HRQOL?; and 2) can we reliably quantify the expected
effect on mortality, hospitalization, and HRQOL that
may follow in future HF trials?
METHODS
This study followed the PRISMA (Preferred Reporting
Items for Systematic Reviews and Meta-Analysis)
guideline (7).
STUDY IDENTIFICATION. We updated the Cochrane
systematic review of RCTs of exercise-based CR in
HF up to February 2017 (8). This search included
the Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE, MEDLINE In-Process,
Embase, CINAHL, PsycINFO, conference pro-
ceedings via Web of Science Core Collection, and
trial registries (World Health Organization Interna-
tional Clinical Trials Registry Platform and
ClinicalTrials.gov). We included RCTs of adults, age
18 years or older, comparing exercise-based CR and
control in HF patients with follow-up of 6 months
or longer for at least 1 of the outcomes. Exercise-based CR was deﬁned as an intervention
that includes exercise training, either alone
or in addition to psychosocial and/or
educational interventions. Controls could
receive standard medical care without any
form of structured exercise training or
advice. We sought to include all RCTs that
reported EC at baseline and follow-up,
whether measured using VO2peak or
6MWT, and at least 1 of the ﬁnal patient-
relevant outcomes of interest (i.e., mortal-
ity, hospitalization, or HRQOL).
Screening of full study reports was under-
taken by 1 of the authors (O.C., J.U.) and
checked by a second author (R.S.T.).
DATA EXTRACTION. For each study, we
extracted the following information: ﬁrst
author, publication year, geographical loca-
tion, sample size and ratio of intervention to
control, study follow-up duration, setting of exercise
training intervention (center- or home-based exercise
program), age (mean), sex (percentage male), left
ventricular ejection fraction (mean), and New York
Heart Association functional class of the patient
population. The continuous outcomes of EC and
HRQOL were extracted at baseline and at the latest
reported follow-up as mean  SD for both exercise
and control groups. The binary outcomes of mortality
and hospitalization were extracted as the number of
patient events at the latest follow-up relative to the
number of patients randomized to each group.
Whenever necessary, an online digitizer (Web-
PlotDigitizer) was used. Missing SDs at baseline or
follow-up were imputed from conﬁdence intervals,
interquartile ranges, or SEs, and missing SDs for
follow-up minus baseline change were estimated
using Cochrane Handbook recommended methods
(9). For trials with more than 1 exercise intervention
arm, we followed the Cochrane Handbook’s approach
for combining groups (9). All data was ﬁrst extracted
by 1 of the authors (O.C.) and then checked by another
(R.S.T.). Trial quality was assessed using the
Cochrane risk of bias tool (10).
STATISTICAL ANALYSIS. Binary outcomes at the
latest follow-up were expressed as an odds ratio (OR),
where OR <1.0 indicated a beneﬁcial effect of
exercise-based CR compared with control. Given the
variation in reporting of outcomes across studies, we
ﬁrst expressed the between-group difference in EC
and HRQOL for each study as a standardized mean
difference and 95% conﬁdence interval (CI). For the
subset of studies that reported HRQOL using the
Minnesota Living With Heart Failure (MLwHF)
FIGURE 1 Study Selection Flow Diagram
6MWT ¼ 6-min walk test; HF ¼ heart failure; HRQoL ¼ health-related quality of life; MLwHF ¼ Minnesota Living With Heart Failure ques-
tionnaire; VO2peak ¼ peak oxygen uptake.
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598questionnaire, weighted mean differences were
calculated, where a negative between group mean
difference (exercise minus control) in MLwHF in-
dicates a greater HRQOL score in the training group
compared to the control group. In the subset of
studies that reported VO2peak (in ml/kg/min) or
6MWT (in meters), we calculated the mean difference
between groups and 95% CI in original units. A posi-
tive mean difference (exercise minus control) indi-
cated greater EC in the training group compared to
the control group.
Statistical heterogeneity was assessed using the I2
statistic (9), and small-study effects and publication
bias were assessed using the Egger test or the Peters
test. All outcomes were pooled using a DerSimonian
and Laird random effects model with continuity
correction when needed.
We calculated commonly reported indicators of
surrogate validation (11). The correlation coefﬁcient
(r) and the R2 for the relationship between treatment
effect differences in EC and each of the ﬁnal out-
comes individually were estimated using weighting
by the inverse of the variance (for the treatment ef-
fect on ﬁnal outcomes). Where possible, the surrogate
threshold effect (STE) was calculated. The STErepresents the intercept of the prediction band of the
regression line with zero effect on the ﬁnal outcome
(12).
We performed sensitivity analyses to assess
whether our ﬁndings changed when: 1) excluding the
largest included trial (HF-ACTION [Heart Failure: A
Controlled Trial Investigating Outcomes of Exercise
Training]) (13); 2) limiting our analysis to studies of
HF with reduced ejection fraction only; or 3) limiting
our analysis to studies at low risk of bias as assessed
by random sequence generation (14) and allocation
concealment (15).
All data analyses were conducted using Stata
version 14.2 (Stata Corp., College Station, Texas)
software.
RESULTS
STUDY SELECTION AND CHARACTERISTICS. A total
of 31 studies and 32 comparison groups (1 study had 2
exercise intervention arms [16]) were included for
analysis (Figure 1).
A summary of included studies is given in Table 1
(details are listed in Online Table 1 with supple-
mental references listed). The nature of exercise
TABLE 1 Summary of Characteristics of Included Trials
Exercise type
Aerobic 23 (72)
Mixed 9 (28)
Exercise length (weeks) 24 (4–60)
Exercise session duration (min) 30 (15–60)
Exercise dose* (min) 2,160 (480–6,000)
Follow-up (months) 6.5 (6–120)
Setting
Center-based 13 (41)
Home-based 7 (22)
Both 12 (37)
Sample size 54 (19–2,331)
Publication date
1990–1999 5 (16)
2000–2009 16 (50)
2010 or later 11 (34)
Single center 27 (84)
Male (%) 81 (42–100)
Age (yrs) 60.5 (51.0–80.5)
Diagnosis
HFrEF only 26 (81)
Values are n (%) or median (range). *Dose ¼ number of weeks of intervention 
number of exercise training sessions per week mean duration of exercise session
(in min).
HFrEF ¼ heart failure with reduced ejection fraction.
TABLE 2 Pooled Exercise Capacity*
Exercise Capacity
(Follow-Up Minus Baseline Change)
VO2peak 6MWT
No. of studies 22 10
WMD (95% CI) 3.10 (2.01–4.20) 41.15 (16.68–65.63)
p value <0.001 0.001
I2 96.6% 85.1%
Egger test p value 0.052 0.806
*DerSimonian and Laird random effects method. Treatment or lower than 1.0
favors exercise intervention; negative WMD favors exercise intervention. Positive
weighted (by inverse variance) changes in exercise capacity values favor the
exercise rehabilitation group. Number of studies, WMD (95% CI), p value for
signiﬁcance of effect size, I2 statistic, and Egger test p value for small-study effect
reported.
6MWT ¼ 6-min walk test; CI ¼ conﬁdence interval; VO2peak ¼maximum oxygen
uptake; WMD ¼ weighted mean difference.
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599training varied across studies with regard to the fre-
quency, duration, and intensity of exercise (Online
Table 1).
RISK OF BIAS. The overall risk of bias assessment
was moderate, although several studies failed to give
sufﬁcient details to assess risk of bias criteria (Online
Table 2). Reporting was found to be considerably
better in more recently published studies.
IMPACTOFEXERCISETRAINING. Exerc i se capac i ty . EC
was reported at follow-up times ranging from 1 to
14 months. In the subset of studies reporting
VO2peak, there was a larger increase in mean pooled
EC with exercise-based CR compared with control
(3.10 ml/kg/min; 95% CI: 2.01 to 4.20; 22 studies;
p < 0.001; I2 ¼ 96.6%) (Table 2, Online Figure 1).
A similar positive ﬁnding for the exercise-based CR
arm was seen in the subset of studies reporting
6MWT (41.15 m; 95% CI: 16.68 to 65.63; 10 studies;
p ¼ 0.001; I2 ¼ 85.1%) (Online Figure 2).
F ina l pat ient- re levant outcomes . There was no
difference in pooled mortality between exercise-
based CR and control (OR: 0.85; 95% CI: 0.71 to 1.01;
26 trials; p ¼ 0.066; I2 ¼ 0%) (Online Figure 3). The
risk of all-cause hospitalization was reduced in the
exercise group compared with control (OR: 0.64; 95%
CI: 0.44 to 0.93; 20 studies; p ¼ 0.02; I2 ¼ 60.3%)
(Table 3, Online Figure 4).HRQOL at baseline and follow-up was reported in
21 comparisons, of which 14 used the disease-speciﬁc
measure, the MLwHF questionnaire (17). Other
HRQOL questionnaires reported were the Kansas City
Cardiomyopathy Questionnaire (13,18), Icelandic
Quality of Life (19), the Chronic Heart Failure Ques-
tionnaire (20,21), the Likert scale for symptoms (22),
and the patients’ global assessment of change in
quality of life (23). Across all HRQOL outcome mea-
sures, the level of HRQOL at follow-up was higher
with exercise-based CR compared with control
(standardized mean difference: 0.48 SDU; 95% CI:
0.73 to 0.24; 21 comparisons; p < 0.0001; I2 ¼
89.5%) (Online Figure 5). When pooling the subgroup
of trials that reported MLwHF follow-up scores, the
level of HRQOL was higher in the exercise-based CR
group (7.24; 95% CI: 11.84 to 2.63; 14 compari-
sons; p ¼ 0.002; I2 ¼ 67.9%) (Online Figure 6). All
patient-relevant outcomes were measured over
follow-up times from a minimum of 3 months up to
120 months.
Eva luat ion of EC as surrogate endpo int . Re-
gression coefﬁcients of determination (R2) and cor-
relation coefﬁcients (r) between the change in EC and
mortality or hospitalization were relatively low
(R2 # 28%; jrj < 0.53) (Table 4). The coefﬁcients for
the slope of the regression line were not signiﬁcantly
different from zero (p > 0.05), conﬁrming no clear
associations between CR intervention effect on EC
and clinical outcomes.
Higher correlations were seen between change in
EC and HRQOL, for example, R2 ¼ 32% and r ¼ 0.57
for the change in 6MWT and MLwHF; R2 ¼ 52%; r ¼
0.72 for the change in VO2peak and all HRQOL
measures. Negative correlation coefﬁcients indicate
that larger CR effects on EC are associated with larger
CR effects on HRQOL (Table 4).
TABLE 3 Pooled All-Cause Mortality, Hospitalization, and HRQOL (Either MLwHF or All Scales)*
Mortality
(All-Cause)
Hospitalization
(All-Cause)
MLwHF
(Follow-Up)
HRQOL
(All Scales)
(Follow-Up)
No. of studies 26 20 14 21
Effect estimate (95% CI) OR: 0.85 (0.71 to 1.01) OR: 0.64 (0.44 to 0.93) WMD: 7.24 (11.84 to 2.63) SMD: 0.48 (0.73 to 0.24)
p value 0.066 0.020 0.002 <0.001
I2 0% 60.3% 67.9% 89.5%
Peters or Egger test: p value Peters: 0.162 Peters: 0.373 Egger: 0.798 Egger: 0.078
*DerSimonian and Laird random effects method. Treatment or lower than 1.0 favors exercise intervention; negative SMD/WMD favors exercise intervention. Positive weighted
(by inverse variance) changes in exercise capacity values favor the exercise rehabilitation group. Number of studies, effect estimates (95% CI), p value for signiﬁcance of effect
size, I2 statistic, and Peters or Egger test p value for small-study effect reported.
HRQOL ¼ Health-related quality of life; MLwHF ¼ Minnesota Living with Heart Failure questionnaire; OR ¼ odds ratio; SMD ¼ standardized mean difference; other
abbreviations as in Table 2.
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600Surrogate threshold effect . Based on the correla-
tion analyses, we estimated STEs for EC and HRQOL.
For the subset of studies reporting VO2peak (Figure 2),
we estimated that an average improvement of 5 ml/
kg/min in VO2peak exercise-based CR versus control isTABLE 4 Surrogacy Validity of VO2peak and 6MWT Vs. Mortality,
Hospitalization, and HRQOL Measures*
Exercise Capacity
(Follow-Up Minus Baseline Change)
VO2peak 6MWT
Mortality (all-cause, log OR)
Coeff (SE) 0.19 (0.08) 0.009 (0.005)
p value 0.035 0.118
R2 28% 28%
P 0.53 0.53
Hospitalization (all-cause, log OR)
Coeff (SE) 0.17 (0.12) 0.01 (0.02)
p value 0.181 0.509
R2 12% 24%
P 0.35 0.49
MLwHF (follow-up value)
Coeff (SE) 1.59 (1.64) 0.13 (0.08)
p value 0.388 0.141
R2 19% 32%
r 0.43 0.57
STE 80 m
HRQOL (all scales, follow-up value)
Coeff (SE) 0.22 (0.07) 0.008 (0.004)
p value 0.013 0.120
R2 52% 27%
r 0.72 0.52
STE (ml/kg/min) 5
*Coeff (SE) and related p value for the slope of the regression line and R2 derived
from least-squares linear regressions weighted by the inverse of variance of the
treatment effect on ﬁnal outcomes. Weighted correlation coefﬁcient (r) is shown.
STE calculated as the value of the treatment effect on the surrogate outcome at
which the linear regression prediction line crosses the null effect line for the
treatment effect on patient-relevant outcomes. Only trials contributing to the
within-study paired analysis were considered.
Coeff ¼ coefﬁcient; STE ¼ surrogate threshold effect; other abbreviations as in
Tables 2 and 3.needed to predict a favorable improvement in HRQOL
with exercise-based CR compared to control. For the
subset of studies reporting 6MWT (Figure 3), we
estimated an STE of 80 m for 6MWT to predict a sig-
niﬁcant improvement in MLwHF with exercise-based
CR versus control. This pattern of link between EC
and ﬁnal outcomes was consistent across all sensi-
tivity analyses (Online Tables 3 to 6).
DISCUSSION
Using trial-level data from RCTs of exercise-based
CR for HF, we formally evaluated the evidence for
EC as a surrogate endpoint for the ﬁnal outcomes of
mortality, hospitalization, and HRQOL. Our results
show an increase in VO2peak or 6MWT with exercise-
based CR to be associated with improvements in
clinical outcomes (24). However, the observed levels
of association indicate EC is a poor surrogate
endpoint for mortality and hospitalization and has
moderate validity for HRQOL. We found an STE for
VO2peak of 5 ml/kg/min and 6MWT of 80 m. Thus,
exercise-based CR would need to increase VO2peak
and 6MWT by this level (or more) to have 95%
conﬁdence interval to be able to demonstrate sig-
niﬁcant improvement in HRQOL in a future trial.
Sensitivity analyses conﬁrmed VO2peak to have
moderate surrogate validity for HRQOL.
IMPLICATIONS FOR PRACTICE. Our study ﬁndings
have signiﬁcant implications for future HF trials.
Contrary to epidemiological (observational) evidence,
our results show that intervention effects on EC are
not predictive of treatment effects on the clinical
events of mortality or hospitalization. However, we
also showed that improvements in EC, if large
enough, can be predictive of important gains in pa-
tient HRQOL.
Surrogate endpoints generally accrue more quickly
than ﬁnal endpoints, thus allowing for RCTs with
FIGURE 2 Results of Regression Analyses Showing the Relationship Between Changes in VO2peak Between Baseline and FU on Log Odds
of Clinical Event (Mortality or Hospitalization) or HRQoL Reported as MLwHF or All Scales
Circles represent a study-level comparison, with sizes proportionate to study weights (based on inverse variance weighting). Dashed gray
lines correspond to the bounds of the 95% conﬁdence interval for the regression line. Solid gray lines correspond to the bounds of the 95%
prediction interval for the regression line. FU ¼ follow-up; OR ¼ odds ratio; SMD ¼ standardized mean difference; VO2 ¼ peak oxygen uptake;
WMD ¼ weighted mean difference; other abbreviations as in Figure 1.
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601shorter follow-up periods and smaller sample sizes.
Reducing trial sample size and duration ensures
faster patient access to new therapies and means that
trials are less expensive, which makes surrogate
endpoints attractive to manufacturers and research
sponsors alike. However, it is important that surro-
gate endpoints be carefully validated, as evidenced
by the dramatic failures of surrogates used for regu-
latory purposes.
Our results are consistent with the review by Fer-
reira et al. (4), which recommended the use of EC as
outcome in HF trials based on qualitative analysis of
results from HF trials showing an improvement in
6MWT was associated with a favorable treatment ef-
fect of morbidity and mortality. This analysis noted
that an increase of 30 to 50 m in 6MWT has been used
in cardiac resynchronization therapy trials in order to
gain pre-market approval. This magnitude of
improvement in EC is somewhat smaller than our
estimated STE of 80 m in the 6MWT. Similarly, our
ﬁnding of an STE of 5 ml/kg/min in VO2peak is
considerably larger than the increase of 6% in
VO2peak (i.e., w1.0 ml/kg/min) needed to predict an
improvement in the primary outcome (time toall-cause mortality or all-cause hospitalization) re-
ported by Swank et al. (25) based on HF-ACTION.
Although based on patient-level data analysis from a
large RCT of exercise-based CR (HF-ACTION), this
later analysis does not take into account the role of
treatment; therefore, it can be used to establish the
prognostic validity of VO2peak but not the association
between treatment effects on VO2peak and treatment
effects on patient-relevant outcomes as measured
across a number of RCTs. In contrast, and in accor-
dance with contemporary recommendations for sur-
rogate endpoint validation (26), the present study
derived STE values from the prediction interval
around the regression line rather than from the 95%
CI based on a meta-analysis of RCTs of exercise-based
CR in HF.
STUDY LIMITATIONS. First, the methods of EC
assessment varied considerably across studies.
Whereas a number of studies reported VO2peak, a
small proportion directly measured VO2peak using
cardiorespiratory testing, and others predicted
VO2peak using a submaximal exercise. However, this
limitation does not apply to the subgroup of studies
that assessed EC using 6MWT. In addition, although
FIGURE 3 Results of Regression Analyses Showing the Relationship Between Changes in 6MWT Between Baseline and FU on Log Odds of
Clinical Event (Mortality or Hospitalization) or HRQoL Reported as MLwHF or All Scales
Circles represent a study-level comparison, with sizes proportionate to study weights (based on inverse variance weighting). Dashed gray
lines correspond to the bounds of the 95% conﬁdence interval for the regression line. Solid gray lines correspond to the bounds of the 95%
prediction interval for the regression line. Abbreviations as in Figures 1 and 2.
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602most studies reported EC at baseline and follow-up,
they did not report the SD of the baseline-follow up
change in EC. For these studies, we imputed the SD
of change (using a correlation coefﬁcient 0.74 from
included trials) (9). Both of these factors might have
introduced measurement error and masked an
underlying association between EC with ﬁnal out-
comes. Second, there was considerable heterogene-
ity in exercise-based intervention applied in the
included RCTs: a wide range in exercise training
dose and variation in whether trials included
educational and psychological cointerventions.
Here, we would argue that such heterogeneity is
implicit in a systematic review and meta-analysis of
a complex intervention such as exercise-based CR
(27). However, it could be argued that restricting
our analyses to exercise-based CR trials limits the
generalizability of our results. However, it is rec-
ommended that the surrogate validation be under-
taken in trials across the same intervention (5).
Third, a number of included RCTs studies had
methodological issues or poor reporting that may
have resulted in their high risk of bias. However,
reassuringly, our ﬁndings were consistent when
limited to the subgroup of trials of low risk of bias.
Fourth, despite excluding trials with follow-up <6
months, the timing of longest assessment acrossstudies varied from 1 to 14 months for EC and from
3 months to 10 years for ﬁnal outcomes. Unfortu-
nately, individual studies did not consistently
report EC and ﬁnal outcomes at repeated time
points, so we could not explore this issue.
CONCLUSIONS
This systematic review and meta-analysis of RCTs of
exercise-based CR shows that treatment effect on EC
is a poor surrogate endpoint for treatment effect on
mortality and hospitalization. However, we found the
effect of exercise-based CR on EC to have moderate
validity as a surrogate endpoint for treatment effect
on HRQOL. Further research is needed to determine
whether our ﬁndings are generalizable across other
HF interventions. Given that the participant-level
ﬁtness response to exercise-based CR can be highly
heterogeneous (28,29), our ﬁndings also need conﬁr-
mation from individual participant data meta-
analyses of exercise-based CR (5).
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Using
data from randomized trials of exercise-based CR for HF,
we formally evaluated the evidence for EC as a surrogate
endpoint for mortality, hospitalization, and HRQOL. EC is
a poor surrogate endpoint for mortality and hospitaliza-
tion but has moderate validity as a surrogate for HRQOL.
In severe and advanced stages of HF, improvements in
independence and the ability to perform daily tasks
become even more important than improvements in
morbidity and mortality. In this respect, linking increases
in EC to HRQOL improvements can be seen as a clinically
relevant ﬁnding.
TRANSLATIONAL OUTLOOK: The use of surrogate
endpoints can improve the efﬁciency of clinical trials by
reducing sample size and duration, thereby promoting
quicker patient access to new therapies. However, to
ensure reliable prediction of ﬁnal patient-related out-
comes, it is important that surrogate endpoints be vali-
dated. Our results show an increase of 5 ml/kg/min in
VO2peak and 80 m for 6MWT can signiﬁcantly predict an
improvement in HRQOL. Further research is needed to
determine whether our ﬁndings can be replicated for
other types of interventions in chronic HF patients and in
other cardiovascular disease populations.
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